<p><h1>Shingles Vaccine Market Size: Growth Outlook from 2024 to 2031, projecting at Market's Trends Analysis by Application, Regional Outlook, and Revenue</h1></p><p><strong>Shingles Vaccine Market Analysis and Latest Trends</strong></p>
<p><p>The shingles vaccine is designed to prevent herpes zoster, commonly known as shingles, which results from the reactivation of the varicella-zoster virus. The vaccine is particularly recommended for older adults, as the risk of shingles increases significantly with age, leading to complications such as postherpetic neuralgia. </p><p>The Shingles Vaccine Market is expected to grow at a CAGR of 15.20% during the forecast period, driven by increasing awareness of the vaccine’s benefits and the rising incidence of shingles cases among aging populations. Innovations in vaccine formulations, such as adjuvanted and live attenuated vaccines, are enhancing efficacy and safety profiles. </p><p>Additionally, government initiatives for vaccination programs and the promotion of preventive healthcare measures are contributing to market growth. The expansion of healthcare infrastructure and efforts to improve access to vaccines in emerging markets further support this upward trend. Furthermore, research into potential vaccines for younger populations may create new opportunities within the market. Overall, the shingles vaccine market is poised for significant expansion, focusing on innovation and accessibility as key drivers.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reportprime.com/enquiry/request-sample/11825">https://www.reportprime.com/enquiry/request-sample/11825</a></p>
<p>&nbsp;</p>
<p><strong>Shingles Vaccine Major Market Players</strong></p>
<p><p>The shingles vaccine market is led by key players such as Merck & Co. and GlaxoSmithKline (GSK). Merck’s Zostavax, an older live attenuated vaccine, is complemented by Shingrix, a newer recombinant vaccine that has shown higher efficacy in preventing shingles and postherpetic neuralgia, significantly influencing the market dynamics.</p><p>Merck’s Shingrix has gained substantial traction since its launch, capturing a significant market share due to its superior efficacy of approximately 90% in adults over 50, positioning it as a favorable option for vaccination. The vaccine's approval and recommendations for adults aged 50 and above have propelled Merck’s sales, driving robust growth and solidifying its market leader status. In 2022, Merck reported revenues exceeding $3 billion from Shingrix, reflecting strong demand and increased vaccination rates.</p><p>GlaxoSmithKline, on the other hand, has also made strides with its vaccine pipeline, but its presence in the shingles vaccine market primarily revolves around Shingrix. GSK’s competitive edge lies in its extensive global distribution network and strategic partnerships, ensuring widespread availability of Shingrix. GSK’s focus on innovation and upcoming therapies presents a promising growth trajectory.</p><p>The shingles vaccine market is set to grow due to rising awareness regarding shingles prevention, growing elderly populations, and recommendations by health authorities. The global market size was valued at approximately $2 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of around 10% through 2030, driven by the increasing enrollment in vaccination programs and sustained efforts in public health initiatives.</p><p>As awareness of the adverse effects of shingles rises, both Merck and GSK are well-positioned for sustained growth, cementing their roles as leading players in this evolving market.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Shingles Vaccine Manufacturers?</strong></p>
<p><p>The shingles vaccine market is poised for significant growth, driven by rising awareness of herpes zoster and increasing vaccination recommendations among adults. Recent data indicates a strong uptick in vaccine uptake, particularly among older populations, spurred by aging demographics and rising healthcare expenditure. The global market is projected to grow at a CAGR of approximately 8-10% through 2030. Innovations in vaccine formulations and expanded indications are likely to further bolster market expansion. Strategic collaborations and government initiatives will play a crucial role in enhancing accessibility, positioning the shingles vaccine market for sustained growth in the coming years.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reportprime.com/enquiry/pre-order/11825">https://www.reportprime.com/enquiry/pre-order/11825</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Shingles Vaccine Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Zostavax</li><li>Shingrix</li></ul></p>
<p><p>The shingles vaccine market primarily consists of two main products: Zostavax and Shingrix. Zostavax is a live attenuated vaccine that provides moderate protection against shingles and postherpetic neuralgia, primarily targeting older adults. In contrast, Shingrix is a recombinant vaccine known for its higher efficacy and longer-lasting immunity, recommended for adults aged 50 and older. Shingrix has gained significant preference due to its superior safety profile and effectiveness, driving a shift in market demand toward this innovative solution for shingles prevention.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reportprime.com/checkout?id=11825&price=3590">https://www.reportprime.com/checkout?id=11825&price=3590</a></p>
<p>&nbsp;</p>
<p><strong>The Shingles Vaccine Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Under 50 Years Old</li><li>50-60 Years Old</li><li>60-70 Years Old</li><li>Above 70 Years Old</li></ul></p>
<p><p>The shingles vaccine market is segmented by age groups to target specific demographics. For individuals under 50, awareness and preventive measures are crucial, emphasizing early vaccination benefits. The 50-60 age group sees increased focus due to rising herpes zoster incidence, advocating for proactive immunization. In the 60-70 range, vaccination becomes essential for health maintenance and reducing complications from shingles. For those above 70, the market prioritizes advanced vaccines to address the higher risk of severe outcomes and enhance immunity against the virus.</p></p>
<p><a href="https://www.reportprime.com/shingles-vaccine-r11825">&nbsp;https://www.reportprime.com/shingles-vaccine-r11825</a></p>
<p><strong>In terms of Region, the Shingles Vaccine Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The shingles vaccine market is experiencing notable growth across multiple regions, with North America and Europe leading the way. North America is projected to capture approximately 45% of the market share, driven by widespread vaccination initiatives. Europe follows closely, holding around 30%. The Asia-Pacific (APAC) region is anticipated to witness rapid expansion, contributing about 15%, with increasing awareness and healthcare access. Meanwhile, China is expected to account for around 10% of the market, reflecting growth potential from its large population and rising healthcare investments.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reportprime.com/checkout?id=11825&price=3590">https://www.reportprime.com/checkout?id=11825&price=3590</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reportprime.com/enquiry/request-sample/11825">https://www.reportprime.com/enquiry/request-sample/11825</a></p>
<p><strong></strong></p>
<p><p><a href="https://medium.com/@paulmcglynn6456/stationary-catalytic-systems-market-share-size-trends-industry-analysis-report-by-application-0b5041df5d82">Stationary Catalytic Systems Market</a></p><p><a href="https://medium.com/@katheleentco/%E9%A3%B2%E7%94%A8%E3%82%B9%E3%83%94%E3%83%AA%E3%83%83%E3%83%84%E5%B8%82%E5%A0%B4%E8%A6%8F%E6%A8%A1-%E3%82%BF%E3%82%A4%E3%83%97%E5%88%A5-%E7%99%BA%E9%85%B5%E3%83%AF%E3%82%A4%E3%83%B3-%E8%92%B8%E7%95%99%E3%82%B9%E3%83%94%E3%83%AA%E3%83%83%E3%83%84-%E3%81%9D%E3%81%AE%E4%BB%96-%E8%A3%BD%E5%93%81%E5%88%A5-%E3%82%B9%E3%83%BC%E3%83%91%E3%83%BC%E3%83%9E%E3%83%BC%E3%82%B1%E3%83%83%E3%83%88-%E5%B0%82%E9%96%80%E5%BA%97-%E3%82%AA%E3%83%B3%E3%83%A9%E3%82%A4%E3%83%B3%E3%82%B7%E3%83%A7%E3%83%83%E3%83%97-%E3%81%9D%E3%81%AE%E4%BB%96-%E3%82%B0%E3%83%AD%E3%83%BC%E3%83%90%E3%83%AB%E7%94%A3%E6%A5%AD%E5%88%86%E6%9E%90-%E5%B8%82%E5%A0%B4%E3%82%B7%E3%82%A7%E3%82%A2-%E6%88%90%E9%95%B7-%E3%83%88%E3%83%AC%E3%83%B3%E3%83%89-2024%E5%B9%B4%E3%81%8B%E3%82%89-1bbb504f0fb9">ポタブルスピリット</a></p><p><a href="https://medium.com/@paulmcglynn6456/network-test-equipment-market-global-market-share-and-ranking-overall-sales-and-demand-forecast-57964c8c6673">Network Test Equipment Market</a></p><p><a href="https://medium.com/@katheleentco/%E3%82%B0%E3%83%AD%E3%83%BC%E3%83%90%E3%83%AB%E4%B8%AD%E5%9B%BD%E7%B1%B3%E9%85%92%E5%B8%82%E5%A0%B4%E3%81%AE%E3%83%88%E3%83%AC%E3%83%B3%E3%83%89%E3%81%A8%E9%9D%A9%E6%96%B0-%E6%9C%AA%E6%9D%A5%E5%BF%97%E5%90%91%E3%81%AE%E5%88%86%E6%9E%90-2024-2031-35799a721a65">中国産ライスワイン</a></p><p><a href="https://issuu.com/reportprime-2/docs/squeeze-rubber-tube-market-size-203_78f6e55f07d364">Squeeze Rubber Tube Market</a></p></p>